Segarra, Elmarjun A.
HRN: 23-57-74 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/01/2023
CO-AMOXICLAV 625MG (TAB)
09/01/2023
09/08/2023
ORAL
625mg
TID
S/p Tonsillectomy
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes